Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PDSB
$0.6592
$
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Next Earnings
2026-02-25
Beta
1.157
Average Volume
Market Cap
Last Dividend
CIK
0001472091
ISIN
US70465T1079
CUSIP
70465T107
CEO
Frank K. Bedu-Addo
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
24
IPO Date
2015-09-30
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval | Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer | GlobeNewsWire | 2026-02-20 08:30:00 |
| PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI | NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer | GlobeNewsWire | 2026-01-28 08:45:00 |
| PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 | Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years | GlobeNewsWire | 2026-01-22 08:45:00 |
| PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint | PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company has submitted a protocol amendment to the U.S. Food & Drug Administration (“FDA”) for its Phase 3 VERSATILE-003 clinical trial. | GlobeNewsWire | 2026-01-09 08:45:00 |
| PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened | PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) traded down 1.9% during trading on Tuesday. The stock traded as low as $0.8746 and last traded at $0.9010. 355,481 shares changed hands during trading, a decline of 40% from the average session volume of 595,547 shares. The stock had previously closed at $0.9186. Analyst Upgrades | Defense World | 2025-12-17 01:51:11 |
| PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan | New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Japan Patent Office has issued Patent No. | GlobeNewsWire | 2025-12-09 08:00:00 |
| PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why | PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2025-12-08 13:01:14 |
| PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) | Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway | GlobeNewsWire | 2025-12-02 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-23 | 2026-02-23 | View Filing |
| 8-K | 2026-02-20 | 2026-02-20 | View Filing |
| 8-K | 2026-01-28 | 2026-01-28 | View Filing |
| 8-K | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-09 | 2026-01-09 | View Filing |
| S-8 | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-12-09 | 2025-12-09 | View Filing |
| 8-K | 2025-12-02 | 2025-12-02 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-10-29 | 2025-10-29 | View Filing |
| 8-K | 2025-09-18 | 2025-09-18 | View Filing |
| S-3 | 2025-08-29 | 2025-08-29 | View Filing |
| 8-K | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-25 | 2025-08-25 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-06-25 | 2025-06-25 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| EFFECT | 2025-06-11 | 2025-06-11 | View Filing |
| CORRESP | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| UPLOAD | 2025-05-30 | 2025-05-30 | View Filing |
| S-3 | 2025-05-27 | 2025-05-27 | View Filing |
| 8-K | 2025-05-22 | 2025-05-22 | View Filing |
| DEFR14A | 2025-05-22 | 2025-05-22 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| DEFR14A | 2025-05-05 | 2025-05-05 | View Filing |
| 8-K | 2025-05-02 | 2025-05-02 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-24 | 2025-04-24 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-13 | 2025-03-13 | View Filing |
| 8-K | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 8-K | 2025-02-28 | 2025-02-28 | View Filing |
| 424B5 | 2025-02-28 | 2025-02-28 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| 8-K | 2025-02-24 | 2025-02-24 | View Filing |
| 8-K | 2025-02-05 | 2025-02-05 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-10-02 | 2024-10-02 | View Filing |
| 8-K | 2024-09-16 | 2024-09-16 | View Filing |
| 8-K | 2024-09-16 | 2024-09-16 | View Filing |
| 424B5 | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-07 | 2024-08-07 | View Filing |
| 8-K | 2024-08-05 | 2024-08-05 | View Filing |
| 8-K | 2024-08-01 | 2024-08-01 | View Filing |
| 4 | 2024-06-25 | 2024-06-25 | View Filing |
| 4 | 2024-06-25 | 2024-06-25 | View Filing |
| 4 | 2024-06-25 | 2024-06-25 | View Filing |
| 4 | 2024-06-25 | 2024-06-25 | View Filing |
| 4 | 2024-06-25 | 2024-06-25 | View Filing |
| 4 | 2024-06-25 | 2024-06-25 | View Filing |
| 8-K | 2024-06-24 | 2024-06-24 | View Filing |
| 8-K | 2024-06-12 | 2024-06-12 | View Filing |
| 10-Q | 2024-05-15 | 2024-05-15 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 8-K | 2024-05-10 | 2024-05-09 | View Filing |
| 8-K | 2024-05-08 | 2024-05-08 | View Filing |
| SC 13G/A | 2024-05-08 | 2024-05-08 | View Filing |
| 4 | 2024-05-02 | 2024-05-02 | View Filing |
| 3 | 2024-05-02 | 2024-05-02 | View Filing |
| 8-K | 2024-05-02 | 2024-05-02 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEFA14A | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| PRE 14A | 2024-04-18 | 2024-04-18 | View Filing |
| S-8 | 2024-03-28 | 2024-03-28 | View Filing |
| 10-K | 2024-03-28 | 2024-03-28 | View Filing |
| 8-K | 2024-03-27 | 2024-03-27 | View Filing |
| 8-K | 2024-03-13 | 2024-03-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Pivot Points Strategy | 20.01% | 0.9 | 14 | 1.27 | 117.19 | 34.34 |
| Momentum Reserve | 13.46% | 1 | 1 | 0.93 | 1.2 | 13.91 |
| Heikin Ashi Strategy | 11.40% | 0.98 | 10 | 0.57 | 0.28 | 22.89 |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxx | xxxxx% | x | x | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | x% | xxxx | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |